Each May, the Lupus Foundation of America unites communities to shed light on lupus, highlighting its impact while advocating ...
In a new study, people with systemic lupus erythematosus (SLE) who developed the disease later in life exhibited notable ...
A study examined the prevalence of people with depression and systemic lupus erythematosus (SLE) and found depression was ...
In a new study published in Lupus Science & Medicine, researchers examined the performance of people with systemic lupus ...
A first person has been dosed with the investigational therapy, AlloNK® (also known as AB-101) for treatment of lupus ...
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of ...
The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy.
We are headed back to Piedmont Park for our Atlanta Walk to End Lupus Now. We can't wait to see all of you as we celebrate YOUR hard work and let Atlanta know that LUPUS MATTERS! Thank you Dr. Maria ...
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for treatment of lupus nephritis (LN). The GALLOP ...
The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy.
The U.S. Food & Drug Administration has granted approval for a Phase 1 study to evaluate the safety and efficacy of investigational therapy, CB-010, for treatment of lupus nephritis (LN). The GALLOP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback